Noncardiac surgery is safe after 6 months after implantation of a DES

Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001

In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history  within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were operated on emergency or had advanced heart disease. In contrast those who received angioplasty at least 6 months prior to surgery showed no increased risk of MACE beyond the type of stent used.

Currently guides suggest waiting at least 6 weeks for the case of a conventional stent and a year after a drug-eluting stent (DES) but according to this study, both stents have an increased risk at the beginning and for both stents the risk reaches base at 6 months. This study is a multicenter retrospective analysis ( Veterans Affairs and Centers for Medicare and Medicaid Services) that included 41989 patients. Between 2000 and 2010 patients 124844 patients were treated with stents, of which 22.5 % were undergoing noncardiac surgery within 2 years. For those who underwent surgery within the first 6 weeks after angioplasty MACE rate was 11.6 % for those operated between 6 weeks and 6 months MACE rate was 6.4 %. Between 6 months and a year and between the first year and the second; the MACE rate was 4.2 % and 3.5 % respectively. The risk of events was also different between patients receiving drug-eluting stents versus bare-metal stents (5.1% versus 4.3 % respectively, p < 0.001 ). However on multivariate analysis only admission for emergency surgery , history of stroke within 6 months after surgery and low cardiac index were predictors of MACE. Of course it is a retrospective registry and this is a major limitation of the study.

Conclusion: 

In patients who undergo noncardiac surgery within 2 years of coronary angioplasty with stent we only observed increased risk of events in those with emergency surgery or advanced heart disease but no difference with respect to the type of stent or at the time of the surgery if this was done at least 6 months later. The emphasis of the guidelines on the stent type and surgical time for drug-eluting stents and conventional, should be reevaluated

Medscape

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...